Skip to main content
Journal cover image

Genomic and clinical predictors of lacosamide response in refractory epilepsies.

Publication ,  Journal Article
Heavin, SB; McCormack, M; Wolking, S; Slattery, L; Walley, N; Avbersek, A; Novy, J; Sinha, SR; Radtke, R; Doherty, C; Auce, P; Craig, J ...
Published in: Epilepsia Open
December 2019

OBJECTIVE: Clinical and genetic predictors of response to antiepileptic drugs (AEDs) are largely unknown. We examined predictors of lacosamide response in a real-world clinical setting. METHODS: We tested the association of clinical predictors with treatment response using regression modeling in a cohort of people with refractory epilepsy. Genetic assessment for lacosamide response was conducted via genome-wide association studies and exome studies, comprising 281 candidate genes. RESULTS: Most patients (479/483) were treated with LCM in addition to other AEDs. Our results corroborate previous findings that patients with refractory genetic generalized epilepsy (GGE) may respond to treatment with LCM. No clear clinical predictors were identified. We then compared 73 lacosamide responders, defined as those experiencing greater than 75% seizure reduction or seizure freedom, to 495 nonresponders (<25% seizure reduction). No variants reached the genome-wide significance threshold in our case-control analysis. SIGNIFICANCE: No genetic predictor of lacosamide response was identified. Patients with refractory GGE might benefit from treatment with lacosamide.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Epilepsia Open

DOI

ISSN

2470-9239

Publication Date

December 2019

Volume

4

Issue

4

Start / End Page

563 / 571

Location

United States

Related Subject Headings

  • 5202 Biological psychology
  • 3209 Neurosciences
  • 3202 Clinical sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Heavin, S. B., McCormack, M., Wolking, S., Slattery, L., Walley, N., Avbersek, A., … Delanty, N. (2019). Genomic and clinical predictors of lacosamide response in refractory epilepsies. Epilepsia Open, 4(4), 563–571. https://doi.org/10.1002/epi4.12360
Heavin, Sinéad B., Mark McCormack, Stefan Wolking, Lisa Slattery, Nicole Walley, Andreja Avbersek, Jan Novy, et al. “Genomic and clinical predictors of lacosamide response in refractory epilepsies.Epilepsia Open 4, no. 4 (December 2019): 563–71. https://doi.org/10.1002/epi4.12360.
Heavin SB, McCormack M, Wolking S, Slattery L, Walley N, Avbersek A, et al. Genomic and clinical predictors of lacosamide response in refractory epilepsies. Epilepsia Open. 2019 Dec;4(4):563–71.
Heavin, Sinéad B., et al. “Genomic and clinical predictors of lacosamide response in refractory epilepsies.Epilepsia Open, vol. 4, no. 4, Dec. 2019, pp. 563–71. Pubmed, doi:10.1002/epi4.12360.
Heavin SB, McCormack M, Wolking S, Slattery L, Walley N, Avbersek A, Novy J, Sinha SR, Radtke R, Doherty C, Auce P, Craig J, Johnson MR, Koeleman BPC, Krause R, Kunz WS, Marson AG, O’Brien TJ, Sander JW, Sills GJ, Stefansson H, Striano P, Zara F, EPIGEN Consortium, EpiPGX Consortium, Depondt C, Sisodiya S, Goldstein D, Lerche H, Cavalleri GL, Delanty N. Genomic and clinical predictors of lacosamide response in refractory epilepsies. Epilepsia Open. 2019 Dec;4(4):563–571.
Journal cover image

Published In

Epilepsia Open

DOI

ISSN

2470-9239

Publication Date

December 2019

Volume

4

Issue

4

Start / End Page

563 / 571

Location

United States

Related Subject Headings

  • 5202 Biological psychology
  • 3209 Neurosciences
  • 3202 Clinical sciences